Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Reported resultsCompany-reported

What was reported

ALAMEDA, Calif., May 13, 2026 (GLOBE NEWSWIRE) – Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants utilizing its proprietary NanoPortal™ technology, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 13, 2026 · Open the source ↗

What the evidence supports

Vivani Medical published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).

What remains unknown

Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.

Source passages

Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.

Press release headlineVivani Medical Reports First Quarter 2026 Financial Results and Provides Business UpdateU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 13, 2026 · Open the source ↗

Press release lead paragraphALAMEDA, Calif., May 13, 2026 (GLOBE NEWSWIRE) – Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants utilizing its proprietary NanoPortal™ technology, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 13, 2026 · Open the source ↗

Revision history

Revision 1 · Oct 28, 2026, 20:51 UTC
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Spotted an error? Tell us. Corrections are published, never silent: see all corrections.

The evidence

The company's own words, furnished to the SEC. Shows what was announced, not that every claim is true.

Sources (1)

Exhibit 99.1 to 8-K
U.S. Securities and Exchange Commission (EDGAR) · retrieved Oct 28, 2026

Dates, kept separate

Event date: 2026-05-13
Source published: 2026-05-13
Sapien Frontier published: 2026-10-28
This revision: 2026-10-28

How this was produced

Extracted automatically from the source (rules-1), then checked: every quote must match the source exactly and every figure must appear in its quote. Anything that fails is dropped or the item is withheld. Methodology.

Share this record

LinkedIn X

Shares carry an evidence card with the record’s own headline and source quote.

Follow Vivani Medical

Get anything new from Vivani Medical in your daily or weekly digest. Pro, $49/month.

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

What was reported

What the evidence supports

What remains unknown

Source passages

Revision history

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

More from Vivani Medical

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight

Vivani Medical reports changes involving its directors or officers (Form 8-K, Item 5.02)